Q32 Bio (QTTB) risk factors, FY2024 10-K

Risks Related to Our Limited Operating History, Financial Position and Need for Capital

1. 01We have incurred significant losses since inception, expect to incur significant losses for the foreseeable future and may not be able to achieve or sustain profitability in the future. We have no products for sale, have not generated any product revenue and may never generate product revenue or become profitable
2. 02establish commercial-scale current good manufacturing practices, or cGMP, capabilities through a third-party or our own manufacturing facility
3. 03We will require substantial additional capital to finance our operations in the future. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce or eliminate clinical trials, product development programs or future commercialization efforts
4. 04obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights
5. 05We have a limited operating history and have no products approved for commercial sale which may make it difficult for you to evaluate our current business and likelihood of success and viability

Risks Related to Discovery, Development and Commercialization

1. 06We face competition from entities that have developed or may develop programs for the diseases we plan to address with bempikibart or other product candidates
2. 07the FDA or other regulatory authorities may require us to submit additional data such as long-term toxicology studies or impose other requirements before permitting us to initiate a clinical trial
3. 08We are substantially dependent on the success of our most advanced product candidate, bempikibart, and our clinical trials of our lead candidate may not be successful
4. 09We previously completed a Phase 1 clinical trial of ADX-097 in healthy volunteers and initiated a Phase 2 clinical trial of this candidate. However, in February 2025, we announced that we were discontinuing the Phase 2 clinical trial of ADX-097 to focus our resources on the bempikibart clinical development program
5. 10If we do not achieve our projected development goals in the time frames we announce and expect, the commercialization of bempikibart or any other product candidates may be delayed
6. 11Our approach to the discovery and development of product candidates is unproven, and we may not be successful in our efforts to build a pipeline of product candidates with commercial value
7. 12third parties being unwilling or unable to satisfy their contractual obligations to us
8. 13We may not be successful in our efforts to identify or discover additional product candidates in the future
9. 14If we encounter difficulties enrolling patients in our future clinical trials, our clinical development activities could be delayed or otherwise adversely affected
10. 15Preliminary, “topline” or interim data from our clinical trials that we announce or publish from time to time may change as more patient data becomes available and are subject to audit and verification procedures
11. 16We may expend our limited resources to pursue a particular product candidate, such as bempikibart, and fail to capitalize on candidates that may be more profitable or for which there is a greater likelihood of success
12. 17Even if regulatory approval is obtained, any approved products may not achieve adequate market acceptance among clinicians, patients, healthcare third-party payors and others in the medical community necessary for commercial success and we may not generate any future revenue from the sale or licensing of such products
13. 18We have never commercialized a product candidate and may lack the necessary expertise, personnel and resources to successfully commercialize a product candidate on our own or together with suitable collaborators

Risks Related to our Intellectual Property

1. 19Our ability to protect our patents and other proprietary rights is uncertain, exposing it to the possible loss of competitive advantage
2. 20Our current or future license agreements may be subject to certain rights retained by third parties
3. 21We cannot ensure that patent rights relating to inventions described and claimed in our current or future licensors pending patent applications will issue or that patents based on us or any of our current future licensors patent applications will not be challenged and rendered invalid and/or unenforceable
4. 22whether the patent applications that we own will result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries
5. 23We enjoy only limited geographical protection with respect to our patents and licensed patents and may not be able to protect our intellectual property rights throughout the world
6. 24Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated if we fail to comply with these requirements
7. 25Issued patents covering one or more of our product candidates could be found invalid or unenforceable
8. 26Patent terms may be inadequate to protect our competitive position with respect to our product candidates for an adequate amount of time
9. 27If we do not obtain patent term extension in the U.S. under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of our marketing exclusivity for our product candidates, if approved, our business may be materially harmed
10. 28Changes to patent laws in the U.S. and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our intellectual property
11. 29We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our product candidates, if approved
12. 30We may be subject to claims challenging the inventorship of our patents and other intellectual property
13. 31We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property
14. 32We may be involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful
15. 33We may become involved in third-party claims of intellectual property infringement, misappropriation or violation, which may prevent or delay our product discovery and development efforts
16. 34we may be forced to try to redesign our product candidates or processes so they do not infringe third-party patents or trademarks or misappropriate or violate other third party intellectual property rights, an undertaking which may not be possible or which may require substantial monetary expenditures and time
17. 35If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
18. 36We may not be able to effectively secure first-tier technologies when competing against other companies or investors
19. 37If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
20. 38Numerous factors may limit any potential competitive advantage provided by our intellectual property rights

Risks Related to Government Regulation

1. 39the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval
2. 40We may not be able to meet requirements for the chemistry, manufacturing and control of our product candidates
3. 41We have and may in the future conduct clinical trials for our product candidates at sites outside the U.S., and the FDA may not accept data from trials conducted in such locations
4. 42Our product candidates for which it intends to seek approval as biologics may face competition sooner than anticipated
5. 43may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor’s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product
6. 44We may face difficulties from healthcare legislative reform measures
7. 45the availability of capital
8. 46Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties
9. 47Even if we are able to commercialize bempikibart or other product candidates, due to unfavorable pricing regulations and/or third-party coverage and reimbursement policies, we may not be able to offer such products at competitive prices which would seriously harm our business
10. 48Governments outside the U.S. tend to impose strict price controls, which may adversely affect our revenue, if any

Risks Related to Our Third Party Relationships

1. 49Future acquisitions or strategic alliances could disrupt our business and harm our financial condition and results of operations
2. 50litigation or other claims in connection with the acquired company, including claims from terminated employees, customers, former stockholders or other third parties
3. 51We rely, and anticipate that we will rely, on third parties to assist in designing, conducting, supervising and monitoring our preclinical studies and clinical trials, and if those third parties perform in an unsatisfactory manner, it may harm our business
4. 52We rely on third parties in the supply and manufacture of our product candidates for our research, preclinical and clinical activities, and may do the same for commercial supplies of our product candidates
5. 53Some state laws also require pharmaceutical companies to comply with specific compliance standards, restrict financial interactions between pharmaceutical companies and healthcare providers or require pharmaceutical companies to report information related to payments to health care providers or marketing expenditures

Risks Related to Our Business, Personnel and Operations

1. 54Our strategic refocus and the associated workforce reduction announced in February 2025 may not result in anticipated cost savings, could result in total costs and expenses that are greater than expected and could disrupt our business
2. 55Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties
3. 56Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CDMOs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
4. 57stakeholders of security incidents. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences
5. 58If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business
6. 59If we are unable to attract and retain qualified key management and scientists, staff, consultants and advisors, our ability to implement our business plan may be adversely affected
7. 60We expect to expand our research, development, delivery, manufacturing, commercialization, regulatory and future sales and marketing capabilities over time, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations
8. 61Our estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all
9. 62We may become exposed to costly and damaging liability claims, either when testing a product candidate in the clinical or at the commercial stage, and our product liability insurance may not cover all damages from such claims
10. 63Litigation costs and the outcome of litigation could have a material adverse effect on our business
11. 64Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited
12. 65The U.S. Congress, the Trump administration, or any new administration may make substantial changes to fiscal, tax, and other federal policies that may adversely affect our business
13. 66Adverse developments affecting the financial services industry could adversely affect our current and projected business operations and our financial condition and results of operations
14. 67We do not anticipate that we will pay any cash dividends in the foreseeable future
15. 68An active trading market for our common stock may not develop and our stockholders may not be able to resell their shares of common stock for a profit, if at all
16. 69Future sales of shares by existing stockholders could cause our stock price to decline
17. 70Our executive officers, directors and principal stockholders have the ability to control or significantly influence all matters submitted to our stockholders for approval
18. 71If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline
19. 72Due to the various factors mentioned herein, and others, the results of any of our prior quarterly or annual periods should not be relied upon as indications of our future operating performance
20. 73We have broad discretion in the use of our cash and cash equivalents and may invest or spend the proceeds in ways with which you do not agree and in ways that may not increase the value of your investment
21. 74Unfavorable global economic conditions could adversely affect our business, financial condition, results of operations or cash flows
22. 75Our certificate of incorporation and bylaws and the provisions under Delaware law could make an acquisition of our company more difficult and may prevent attempts by our stockholders to replace or remove out management
23. 76require the approval of the holders of at least 66.67% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws

Risks Related to Our Operations Following the Merger

1. 77We may be unable to successfully integrate Homology’s and Legacy Q32’s businesses and realize the anticipated benefits of the Merger
2. 78potential unknown liabilities and unforeseen increased expenses, delays or regulatory conditions associated with the Merger
3. 79Stockholders could file lawsuits relating to the Merger
4. 80We will continue to incur additional costs and increased demands upon management as a result of complying with the laws and regulations affecting public companies
5. 81Once we are no longer a smaller reporting company or otherwise no longer qualify for applicable exemptions, we will be subject to additional laws and regulations affecting public companies that will increase our costs and the demands on management and could harm our operating results and cash flows
6. 82If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired
7. 83place. Our remediated controls have been operating for a sufficient period of time and we have concluded, through testing, that these controls are operating effectively and that the material weakness is remediated as of December 31, 2024